ArticleThe Saudi dental journal2026
Comparative radioprotective effects of ascorbic acid and telmisartan, alone and in combination, on gamma-irradiated mandibular bone: an experimental rat study.
Article in The Saudi dental journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was purposed to assess the radioprotective influences of ascorbic acid and Telmisartan, solitary and in combination, on rats exposed to gamma radiation. After different treatment regimens, the study assessed radiographic and histopathological outcomes in bone tissue. Four groups of forty male albino rats were created casually (n = 10). All groups were subjected to fractionated gamma radiation (6 Gy), 2 Gy day after day, three times per week. Group 1 (R) was subjected to fractionated gamma radiation only. Group 2 (MR) received Telmisartan 12 mg/kg orally once/day for 7 days before radiation. Group 3 (CR) received 200 mg/kg orally once/day for 7 days, Ascorbic Acid before radiation. Group 4 (MCR) received Telmisartan 12 mg/kg orally once/day for 7 days, and Ascorbic Acid 200 mg/kg orally once/day for 7 days before radiation. All groups were divided into two subgroups based on two-time intervals (3 days and 10 days). The efficacy of the treatments was evaluated through histological analysis and CBCT, or cone beam computed tomography, for bone density examination. Radiographically, the highest values of bone density measured after 3 days were for the MCR group, while the lowest values of bone density measured after 3 days were for the R group. The histological examination revealed a notable distinction between the 4 groups, with enhanced early matrix deposition in the MCR group at 3 days. The Haversian canals appeared wide and filled with RBCs; also, many reversal lines can be easily noticed and showing that the bone is highly compact with stenosis of Haversian canals at 10 days. A Combination of ascorbic acid with telmisartan demonstrated superiority over ascorbic acid and telmisartan monotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.